Milestones hit by ASX health stocks
We run the ruler over ASX health stock quarterlies, with Bioxyne achieving record Q2 FY25 trading revenue.
We run the ruler over ASX health stock quarterlies, with Bioxyne achieving record Q2 FY25 trading revenue.
ASX rises despite Wall Street dip, Alibaba’s AI shakes Nvidia, Lovisa hit with class action and IGO posts quarterly earnings loss.
Smart money is flowing for Omega Oil & Gas, with minted energy investor Tri-Star Group boosting its stake to 19.9% as part of a $7m raising.
Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy treatment.
Lithium demand will continue to grow from technology stretching far beyond electric vehicles, says PLS boss Dale Henderson.
Boss Energy’s Duncan Craib thinks a uranium price breakout is still on the way after responding to sceptics with a strong December quarter.
NT gold stock Emmerson says White Devil resource is a key milestone, while Boss success leads uranium shares higher.
ASX nears record high on inflation drop and rate cut bets, while Microsoft probes DeepSeek over data breach.
Mesoblast shares fell about 7% after a $260m placement following FDA approval for its cell therapy treatment remestemcel-L in December.
ASX rebounds, Aussie CPI drops to 2.4%, and wine exports jump 34% thanks to China.
Having finally won US marketing approval, Cyclopharm has signed up the nation’s biggest private and public hospital groups.
Chinese AI startup DeepSeek is shaking up the market, sparking debate on whether smaller players could outshine big tech.
Fortescue emerged as the ‘logical’ acquirer of the Blacksmith iron ore project in the Pilbara amid bearish iron ore forecasts.
Victoria’s new roadmap has been welcomed by mineral sands and rare earths companies looking to bring critical new supply sources online.
Nasdaq and ASX tech stocks dive as debut of bargain Chinese AI model DeepSeek causes US$590bn Nvidia wipeout.
Fortescue has made a $254m takeover bid for iron ore developer Red Hawk Mining, owner of the Blacksmith project in WA’s Pilbara.
The ASX closed flat as Chinese AI disruptor DeepSeek spooked Nasdaq, tanked Nvidia and infected local tech stocks.
Fraser Palamara investigates the Fortescue acquisition of Red Hawk Mining and the largest iron ore deposits in the Pilbara held by a junior.
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
As we look towards the rest of 2025, Sprott’s latest report breaks down the big themes that will shape the year ahead.
Queensland’s gas prospects – particularly from the frontier Taroom Trough – have the potential to meet east coast demand.
Cancer is a leading cause of death worldwide but several ASX biotechs are focused on early detection and treatment to improve prognosis.
US small caps are tipped to be one of the best performing sectors under Donald Trump’s business-friendly policies.
ASX ticks higher as Trump shakes things up, and BoJ hikes rates sending some volatility for the Yen.
Analysts say lithium fundamentals could improve despite Donald Trump’s dumping of Joe Biden’s EV policy.
ASX slips despite Wall Street bounce, tech stocks shine after Netflix surge, Musk calls out Trump’s AI plan.
Lithium miner Liontown is keeping its head above water despite opening its Kathleen Valley mine in a deteriorating market.
ASX lifts, tech stocks fly high on Trump’s US$500bn AI promise, while miners drop as tariff talk heats up.
Antipa Minerals could be on the cusp of something great, with a record Aussie gold price enhancing the value of its Minyari Dome project.
With the inauguration done and dusted, US-focused Australian healthcare stocks await the fallout of the latest Trump era.
Tony Rovira backed Lycaon soars as investors await exploration results from Stansmore following maiden drilling in December last year.
Despite a stronger US dollar since Trump’s election win, gold could still rise to US$3000/oz this year, Commbank’s Vivek Dhar says.
As demand for magnet rare earths heats up, REE plays could be primed to take copper’s place in Queensland’s’ Mt Isa region.
Morgans analyst Scott Power says there’s been a rotation back into small healthcare stocks as EBR Systems records a massive monthly gain.
ASX ticks up after Wall Street’s record rally, Trump pushes for more oil, and IGO rises as it dumps lithium refinery expansion.
Trump has pulled the US out of the Paris climate deal again, but according to UTS markets will remain resilient despite the exit.
The ASX 300 metals and mining index fell this week as iron ore majors reported lower prices in a string of production reports.
Fraser Palamara investigates the IGO decision to put the brakes on its Kwinana refinery in a blow for Australia’s downstream industry.
ASX climbs as Trump (and his official meme coin) grabs spotlight; miners surge on iron ore boost; Bitcoin dips and Star Entertainment drops.
Various financial market experts weigh-in on global expectations leading up to and following US President-elect Donald Trump’s inauguration.
Commodities are on fire, with metals and energy surging, tariffs pushing copper up, and silver set to shine in 2025.
Dive into the deal between ASX junior Koonenberry Gold and gold giant Newmont and explore why NSW’s Lachlan Fold Belt is so attractive.
Gold prices could hit record highs this quarter, driven by a perfect economic storm orchestrated by Donald Trump.
AusQuest’s successful initial holes have offered a glimpse into the huge potential of its Cangallo porphyry copper project in southern Peru.
Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.
ASX drops with iron ore miners hit by weaker commodities, tech stocks soar, Myer merger gets the green light.
AusQuest’s copper and gold hits at its Cangallo project in Peru are just the beginning after the porphyry discovery powered a near 200% gain.
Fraser Palamara delves into the AusQuest discovery of large-scale Peruvian copper which doubled its share price.
Tony ups his top mining stocks with Saturn Metals, now back on the ascent with a large collection of gold and some eye-opening results.
West Australian gold explorer Accelerate Resources has a new strategy thanks to a new acquisition near the prolific Super Pit.
Sterilisation device maker Nanosonics flags 120% December half earnings boost and a solid start to 2025.
The return of US President Donald Trump has ASX miners and explorers hopeful it could stoke the development of Arizona’s copper mines.
Keen on critical minerals? Pengana’s James McDonald believes these companies with processing technologies have the right stuff.
Paladin and Boss shareholders are dreaming of breaking the curse of the ASX’s uranium shorters after the former’s strong operating result.
The ASX pushed higher on Wednesday. Tech stocks soared on Trump’s $500b AI plan, while Canada tariffs sent uranium stocks up.
In our new column Counter Cycle, Nero Resource Fund founder and co-manager Rusty Delroy says tin is one of his key commodity picks.
Guy dives into bauxite developer Canyon Resources and a BFS already showing some impressive numbers before a sharp uptick in price.
Fraser Palamara looks at a Viridis Mining and Minerals resource now entrenched as the globe’s highest MREO grade IAC project.
The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.
The supplement outfit’s Australian Open sponsorship exposes its brand to 300 million Chinese viewers.
Oil rigs are firing up, decommissioning’s a $60bn goldmine, and Bhagwan’s eyeing renewables and defence for the long haul.
DLE could play a pivotal role in reducing the impact of a looming lithium supply deficit.
Gold juniors are catching the wave of high prices, drilling down in the hunt for new discoveries as investors catch a case of gold fever.
ASX pares gains after Trump’s tariffs threat sends nerves through the market. Meanwhile, Bitcoin slips as it awaits a bit more clarity from the new POTUS.
ASX miners are entering the trenches for their quarterly showdowns with analysts, with BHP and LTR’s December reports impressing.
ASX lifts with banks, BHP; Trump boosts markets, Liontown triples output and Northern Star is on track.
ASX expected to drop on Wednesday; Nvidia surges 7%. Flutter Entertainment falls 7% due to Illinois sports betting tax
DeSoto Resources got off to a flyer this morning, on the back a new rare earths acquisition in the NT.
Local markets were down again this morning, with the benchmark dropping sharply at open to be around -0.75% at lunchtime, as the market digested some unpleasant news from the ABS about the Consumer Price Index.
Aussie stocks fell 1pc on rising inflation. IAG hit by class action lawsuit. IMF ups China’s growth forecast to 5pc.
Good morning, and Happy Thursday! Here’s everything you need (and some stuff you don’t need) to know before the ASX opens today.
Local markets have completed a worrisome trifecta this morning, losing ground for the third session in a row after a woeful effort on Wall Street overnight set the stage for more losses.
After more than US$3.5 TRILLION was wiped off the S&P 500 overnight, niobium rises. And wait, is nickel back in vogue?
Local investors found relief as the ASX resisted the global markets decline, while the RBA maintained its current policies.
Hydrogen driller Hyterra gets $21.9m investment from FMG and MC Mining flies on US$90m Chinese investment in South African coal.
Miners shot higher but Web Travel Group plunged after a trading update revealed declining EBITDA margins despite increased Total Transaction Value and bookings.
Radiopharm Theranostics appears to be emerging from unloved status to that of a genuine contender in the red-hot radiopharmaceutical sector.
Drill results have Tony Leibowitz and John Young’s lithium play Astute Metals on the up; White House cash lifts Ioneer and Element 25.
The ASX edged up on Monday, with Trump in focus and banks propping things up locally. Meanwhile, Bitcoin and crypto dipped and the Star tanked.
With the US regulator ticking off its manufacturing facilities, EBR is girding for approval of its novel heart lead in April and commercialisation by the end of the year.
Original URL: https://www.news.com.au/finance/business/stockhead/news/page/3